Prelude Capital Management’s CRISPR Therapeutics CRSP Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-15,000
| Closed | -$590K | – | 1145 |
|
|
2024
Q4 | $590K | Buy |
+15,000
| New | +$590K | 0.04% | 455 |
|
|
2024
Q1 | – | Hold |
0
| – | – | – | 1238 |
|
|
2023
Q4 | – | Hold |
0
| – | – | – | 1034 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 1581 |
|
|
2021
Q4 | – | Sell |
-2,117
| Closed | -$237K | – | 1636 |
|
|
2021
Q3 | $237K | Buy |
2,117
+2
| +0.1% | +$224 | 0.01% | 956 |
|
|
2021
Q2 | $342K | Buy |
+2,115
| New | +$342K | 0.01% | 919 |
|
|
2020
Q4 | – | Sell |
-1,537
| Closed | -$129K | – | 928 |
|
|
2020
Q3 | $129K | Sell |
1,537
-3,413
| -69% | -$286K | 0.01% | 614 |
|
|
2020
Q2 | $364K | Buy |
+4,950
| New | +$364K | 0.02% | 361 |
|
|
2019
Q3 | – | Sell |
-7,446
| Closed | -$351K | – | 1256 |
|
|
2019
Q2 | $351K | Buy |
+7,446
| New | +$351K | 0.02% | 332 |
|
|
2018
Q3 | – | Sell |
-5,078
| Closed | -$298K | – | 1395 |
|
|
2018
Q2 | $298K | Sell |
5,078
-6,053
| -54% | -$355K | 0.02% | 526 |
|
|
2018
Q1 | $509K | Sell |
11,131
-13,975
| -56% | -$639K | 0.04% | 384 |
|
|
2017
Q4 | $589K | Buy |
+25,106
| New | +$589K | 0.05% | 329 |
|